Tarsus posts Q2 net loss $31.4M, gets FDA nod for XDEMVY, raises $100M

Tarsus Pharmaceuticals, Inc.

2023-Q2 EPS reported -$2.05 revenue$2,500,000

Net loss of $31.4M in Q2 2023 vs $5.7M loss in Q2 2022; no license revenue ($15.3M in prior year).
Cash and marketable securities $178.2M at June 30, 2023; gross proceeds of $100M from August 2023 equity offering.
FDA approved XDEMVY (lotilaner ophthalmic solution) 0.25% for Demodex blepharitis on July 24, 2023; launch expected end of August 2023.
Completed enrollment of Galatea Phase 2a trial evaluating TP-04 for Rosacea; topline data expected in 1H 2024.
Recruited 85-person sales force targeting ~15K optometrists/ophthalmologists; deployed by end of August.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Tarsus Pharmaceuticals, Inc. reported the second quarter ended June 30, 2023 results: net income net loss of $31.4 million.

Period: the second quarter ended June 30, 2023
Net income: net loss of $31.4 million
Result: reported results

Exact text from the filing

Second quarter net loss for 2023 was $31.4 million, compared to a net loss of $5.7 million for the same period in 2022

View on SEC.gov

Browse all earnings releases →

Tarsus Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001819790-23-000070

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.